OTIC Otonomy, Inc. gains 45% Jul 20, 2017

Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of diseases and disorders of the ear in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTO-104, sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in a Phase 1 clinical safety trial for the treatment of tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California. http://www.priceseries.com/trade/OTIC-Otonomy-Inc-stock-gains-45-percent-a-Trade-Record-by-priceSeries-2017060820170720.html